Team Change
Main Sequence promoted Dr Elaine Stead from Principal to Partner, strengthening leadership as the firm builds toward Fund 4. Stead leads the healthcare thesis and portfolio.
Elaine Stead promoted to Partner at Main Sequence
OCT 13, 2026
New Fund
Main Sequence is targeting $400 million for its fourth fund, backed by two portfolio unicorns (Gilmour Space, Advanced Navigation) and $75M in pre-committed government capital. Targeting first close by end of 2026.
Main Sequence targets $400M for Fund 4